Cannabix Enters Sales Distribution Agreement with Alco Prevention Canada for BreathLogix Autonomous Alcohol Breathalyzer
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) has signed a non-exclusive distribution agreement with Alco Prevention Canada for North America to distribute its BreathLogix autonomous alcohol breathalyzer devices. Alco Prevention, based in Montreal, has 4,000 points of sale and 45 agents worldwide.
The BreathLogix device features patent-pending pre-calibrated cartridge technology, eliminating the need for costly calibration equipment and technician visits. The system autonomously performs alcohol screening, captures user photos for identity confirmation, and delivers real-time BAC results with automated reporting via text, email, and web portal.
The device is currently being used by the Friedel Clinic in Montana under the 24/7 Sobriety Program, demonstrating cost and time savings by eliminating the need for dedicated screening administrators. The company is in discussions with additional distributors in North America and other regions.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) ha firmato un accordo di distribuzione non esclusivo con Alco Prevention Canada per la distribuzione in Nord America dei suoi dispositivi autonomi BreathLogix per il test dell’alcol nel respiro. Alco Prevention, con sede a Montreal, conta 4.000 punti vendita e 45 agenti in tutto il mondo.
Il dispositivo BreathLogix utilizza una tecnologia brevettata di cartucce pre-calibrate, eliminando la necessità di costose apparecchiature di calibrazione e interventi tecnici. Il sistema esegue autonomamente lo screening dell’alcol, cattura foto degli utenti per confermare l’identità e fornisce risultati BAC in tempo reale con report automatici via SMS, email e portale web.
Il dispositivo è attualmente utilizzato dalla Friedel Clinic in Montana nell’ambito del programma 24/7 Sobriety, dimostrando risparmi di tempo e costi grazie all’eliminazione della necessità di amministratori dedicati allo screening. L’azienda è in trattative con altri distributori in Nord America e in altre regioni.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) ha firmado un acuerdo de distribución no exclusivo con Alco Prevention Canada para distribuir en Norteamérica sus dispositivos autónomos BreathLogix para medir el alcohol en el aliento. Alco Prevention, con sede en Montreal, cuenta con 4,000 puntos de venta y 45 agentes en todo el mundo.
El dispositivo BreathLogix incorpora una tecnología patentada de cartuchos pre-calibrados, eliminando la necesidad de costosos equipos de calibración y visitas de técnicos. El sistema realiza de forma autónoma el control de alcohol, captura fotos de los usuarios para confirmar su identidad y entrega resultados de BAC en tiempo real con informes automáticos vía texto, correo electrónico y portal web.
Actualmente, el dispositivo es utilizado por la Friedel Clinic en Montana dentro del programa 24/7 Sobriety, demostrando ahorros de tiempo y costos al eliminar la necesidad de administradores dedicados al control. La empresa está en negociaciones con otros distribuidores en Norteamérica y otras regiones.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF)는 북미 지역에서 자율형 음주 측정기인 BreathLogix를 유통하기 위해 Alco Prevention Canada와 비독점 유통 계약을 체결했습니다. 몬트리올에 본사를 둔 Alco Prevention은 전 세계에 4,000개의 판매 지점과 45명의 에이전트를 보유하고 있습니다.
BreathLogix 장치는 특허 출원 중인 사전 보정 카트리지 기술을 적용하여 비용이 많이 드는 보정 장비와 기술자 방문이 필요 없습니다. 이 시스템은 자율적으로 알코올 검사를 수행하고, 사용자 사진을 촬영해 신원을 확인하며, 실시간 BAC 결과를 문자, 이메일, 웹 포털을 통해 자동 보고합니다.
이 장치는 현재 몬태나의 Friedel Clinic에서 24/7 금주 프로그램 하에 사용 중이며, 전담 검사 관리자 없이도 시간과 비용을 절감하는 효과를 입증했습니다. 회사는 북미 및 기타 지역의 추가 유통업체와 협의 중입니다.
Cannabix Technologies Inc. (CSE : BLO) (OTC PINK : BLOZF) a signé un accord de distribution non exclusif avec Alco Prevention Canada pour distribuer en Amérique du Nord ses appareils autonomes BreathLogix de dépistage de l’alcoolémie par souffle. Alco Prevention, basé à Montréal, compte 4 000 points de vente et 45 agents à travers le monde.
L’appareil BreathLogix utilise une technologie de cartouches pré-calibrées brevetée, éliminant le besoin d’équipements coûteux de calibration et d’interventions techniques. Le système effectue de manière autonome le dépistage de l’alcool, capture des photos des utilisateurs pour confirmer leur identité, et fournit des résultats BAC en temps réel avec des rapports automatisés par SMS, email et portail web.
L’appareil est actuellement utilisé par la clinique Friedel dans le Montana dans le cadre du programme Sobriété 24/7, démontrant des économies de temps et de coûts en supprimant le besoin d’administrateurs dédiés au dépistage. L’entreprise est en discussion avec d’autres distributeurs en Amérique du Nord et dans d’autres régions.
Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) hat eine nicht-exklusive Vertriebsvereinbarung mit Alco Prevention Canada für Nordamerika unterzeichnet, um seine autonomen BreathLogix-Alkoholatemtestgeräte zu vertreiben. Alco Prevention mit Sitz in Montreal verfügt über 4.000 Verkaufsstellen und 45 Agenten weltweit.
Das BreathLogix-Gerät verfügt über eine patentierte, vorkalibrierte Kartuschentechnologie, die den Bedarf an teurer Kalibrierungsausrüstung und Technikerbesuchen überflüssig macht. Das System führt eigenständig Alkoholtests durch, nimmt Nutzerfotos zur Identitätsbestätigung auf und liefert Echtzeit-BAC-Ergebnisse mit automatisierten Berichten per SMS, E-Mail und Webportal.
Das Gerät wird derzeit von der Friedel Clinic in Montana im Rahmen des 24/7 Sobriety-Programms eingesetzt und zeigt Zeit- und Kosteneinsparungen, da keine speziellen Testadministratoren benötigt werden. Das Unternehmen führt Gespräche mit weiteren Vertriebspartnern in Nordamerika und anderen Regionen.
- Non-exclusive distribution agreement secured with established distributor having 4,000 points of sale
- Patent-pending technology reduces maintenance costs and eliminates need for technician visits
- Real-world implementation proving cost and time savings for clients
- Additional distribution discussions ongoing for market expansion
- Non-exclusive nature of distribution agreement may limit competitive advantage
- Success dependent on market adoption and competition in breath testing segment
Cannabix has developed an autonomous alcohol breathalyzer screening device for employers and a range of industries and safety settings
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to report that it has entered into a non-exclusive distribution agreement (“Agreement”) with Alco Prevention Canada (“Alco Prevention”) for North America for its BreathLogix autonomous (unmanned) alcohol breathalyzer devices (Figures 1 and 2). The Company is in discussions with additional distributors in North America and elsewhere.
Alco Prevention, based in Montreal has 4,000 points of sale and is represented by 45 agents worldwide. Alco Prevention offers consumers electronic breathalyzers, breathalyzer rentals for corporate events, training programs, intervention policies and procedures as well as drug screening tests.
Stephane Maurais, General Manager of Alco Prevention stated, “The Breath Logix alcohol device is one the most compact and feature rich devices I have seen in a long time. The device is well suited for employer pre-access, work sites, construction, bars, hotels, restaurants and other safety sensitive environments. The device allows employees and patrons to self-test for breath alcohol, avoiding the cost of having to pay an administrator –this saves time and money for customers and makes workplace safety programs easier to deploy. We are very pleased to represent this Canadian built product.”
Rav Mlait, CEO of Cannabix Technologies stated, “Cannabix is delivering truly innovative new technologies in breath testing to the marketplace. Breath testing for marijuana and alcohol is a growing segment, ripe for innovation and disruptive technologies –this has been our focus, and we look forward to reaching new milestones in 2025.”
Figure 1. BreathLogix Alcohol Screening Devices
Figure 2. BreathLogix Alcohol device available with contactless and straw modes for rapid pre-access alcohol screening
BreathLogix Alcohol Screening Devices
The Company’s BreathLogix unmanned alcohol screening devices hosts several features including patent pending pre-calibrated cartridge technology which will allow administrators to easily maintain their devices, and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance. The devices can be used for pre-access alcohol testing, random testing, start-of-shift testing, pre-employment testing, return-to-work testing and post-incident testing.
BreathLogix autonomously checks the sobriety of a user and can take a picture to confirm and record identity while a breath sample is being delivered. Upon detection of positive breath alcohol result, the device will deliver a precise Blood Alcohol Content (BAC) level on the screen, and send a real-time test report via text message, e-mail and to a dedicated web portal. Furthermore, the system logs user test reports for incident reporting and historical investigations.
For example, under the 24/7 Sobriety Program (deployed in several US states to reduce the re-arrests of individuals previously convicted of driving while under the influence of alcohol through daily breath testing) the BreathLogix device is currently helping the Friedel Clinic (Montana) save money, time and resources by autonomously collecting breath samples from clients on a daily basis, eliminating the need for dedicated in-house alcohol screening administrators using conventional handheld devices.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana and alcohol breath technologies for workplaces, law enforcement and other settings. Breath testing for delta-9 THC (the primary psychoactive ingredient in cannabis) focuses on recent marijuana use. Cannabix is the developer of the BreathLogix autonomous alcohol screening device for organizations who strive to improve alcohol safety and monitoring.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at info@cannabixtechnologies.com
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies ; the completion of pre-validation or validation testing described in this news release; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ed76ae95-1497-442d-9080-559a53b5426d
https://www.globenewswire.com/NewsRoom/AttachmentNg/f1016da3-33cd-4ca4-ad4c-2b2538da2a3b
FAQ
What are the key features of Cannabix's BreathLogix alcohol screening device (BLOZF)?
How does the BreathLogix distribution agreement with Alco Prevention impact BLOZF's market reach?
What types of testing can the BreathLogix device perform for employers?
How is the BreathLogix device being implemented in real-world applications?
